Ck7 ck20 positive tumors are cancers that express both **cytokeratin 7 (CK7)** and **cytokeratin 20 (CK20)** proteins, identified through immunohistochemistry to determine their type and origin.
Immunohistochemistry uses antibodies to detect specific proteins in tumor cells. CK7 and CK20 are markers often used to identify the primary site of epithelial tumors. A tumor that tests positive for both suggests a specific type of cancer, such as pancreatic or ovarian cancer.
The most common CK7/CK20-positive tumors include:
These markers help pathologists distinguish between different types of cancers, which is critical for treatment planning. For example, a CK7-positive/CK20-negative profile may suggest lung or breast cancer, while a CK7-positive/CK20-positive profile is more indicative of pancreatic or ovarian cancer.
Many assume that CK20 positivity always indicates colorectal cancer. However, studies show that about 10-20% of pancreatic and ovarian cancers can also express CK20. This variability underscores the importance of additional testing alongside immunohistochemistry.
A patient presents with a suspected pancreatic tumor. Immunohistochemistry reveals the tumor is CK7-positive and CK20-positive. This profile supports a diagnosis of pancreatic adenocarcinoma, guiding the oncologist's treatment approach.
For more on biomarkers in cancer diagnosis, see our guide on anti-HBc positive results.